Translating Trial Outcomes & Molecular Properties to the Real World

Dr. Marion Munk talks about real-world evidence (RWE) for anti-VEGF therapies compared to randomised clinical trials (RCTs). RCTs, designed to demonstrate drug efficacy in ideal conditions, include a narrow patient population, unlike RWE, which reflects broader, more variable clinical scenarios. Early RWE for ranibizumab revealed limited visual gains due to undertreatment, while brolucizumab data showed mixed outcomes and safety concerns. For faricimab, switching studies often showed no significant functional benefits or extended treatment intervals compared to aflibercept. Other RWE studies highlighted challenges with extending intervals beyond 8 weeks, underscoring the complexities of translating RCT findings to real-world clinical practice.